This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Bacterin International (BONE) Is Gaining Today

NEW YORK (TheStreet) -- Bacterin International (BONE) is gaining on Thursday on the announcement of positive reactions to its OsteoSponge bone graft and after posting better-than-expected fiscal 2013 results.

By midday, shares had added 23.8% to $1.04.

Trading volume of 5.8 million was 36 times higher than its three-month daily average.

The nano-cap was surging after the results of its OsteoSponge bone graft were published in Orthopedics, a peer-reviewed journal. The article noted positive developments in 25 patients who underwent foot and ankle arthrodesis, with 96% showing radiographic fusion at 6 and 12 months postop.

Must Read: Why Infinera (INFN) Is Gaining Today

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

"We have spent a considerable amount of effort and resources supporting the clinical efficacy of our products through peer-reviewed publications in recent years and the results of this study further serve as testament to our role as a leader in the orthobiologic sector," said chief scientific officer Dr. Gregory Juda in a statement.

Separately, after the bell Wednesday, the bone graft developer reported its fiscal 2013 results.

In the 12 months to December, the Belgrade, Mont.-based business generated $33.1 million in revenue, $240,000 higher than analysts surveyed by Thomson Reuters had expected. A net loss of 24 cents a share was 4 cents narrower than analysts had forecast.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BONE $2.80 2.94%
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs